Premium
Relationship Among Fatty Liver, Specific and Multiple‐Site Atherosclerosis, and 10‐Year Framingham Score
Author(s) -
Pais Raluca,
Redheuil Alban,
Cluzel Philippe,
Ratziu Vlad,
Giral Philippe
Publication year - 2019
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.30223
Subject(s) - steatosis , medicine , fatty liver , framingham risk score , odds ratio , coronary atherosclerosis , cardiology , gastroenterology , confidence interval , diabetes mellitus , coronary artery disease , endocrinology , disease
Despite a well‐documented increase in the prevalence of subclinical atherosclerosis in patients with steatosis, the relationship among steatosis and atherosclerosis, specific atherosclerotic sites, multiple‐site atherosclerosis, and cardiovascular risk prediction is incompletely understood. We studied the relationship among steatosis, atherosclerosis site, multiple‐site atherosclerosis, coronary artery calcification (CAC), and 10‐year Framingham Risk Score (FRS) in 2,554 patients with one or more cardiovascular risk factors (CVRF), free of cardiovascular events and other chronic liver diseases, and drinking less than 50 g alcohol/day. All patients underwent arterial ultrasound (carotid [CP] and femoral [FP] plaques defined as intima‐media thickness (IMT) > 1.5 mm), coronary computed tomography scan (severe CAC if ≥ 100), 10‐year FRS calculation, and steatosis detection by the fatty liver index (FLI, present if score ≥ 60). Patients with steatosis (36% of total) had higher prevalence of CP (50% versus 45%, P = 0.004) and higher CAC (181 ± 423 versus 114 ± 284, P < 0.001) but similar prevalence of FP (53% versus 50%, P = 0.099) than patients without steatosis. Steatosis was associated with carotid IMT and CAC, but not with FP, independent of age, diabetes, hypertension, and tobacco use ( P < 0.001). Fifty‐three percent of patients had at least 2‐site atherosclerosis and steatosis was associated with at least 2‐site atherosclerosis independent of age and CVRF (odds ratio = 1.21, 95% confidence interval 1.01‐1.45, P = 0.035). Sixty‐four percent of patients with steatosis had a FRS score of 10% or more. FLI was associated with FRS beyond the CVRF or the number of atherosclerosis sites ( P < 0.001). Adding FLI to CVRF predicted an FRS greater than or equal to 10% better than CVRF alone (area under the receiver operating characteristic curve = 0.848 versus 0.768, P < 0.001). Conclusion: Steatosis is associated with carotid and coronary, but not femoral atherosclerosis, and with cardiovascular mortality risk. The multiple‐site involvement and quantitative tonic relationship could reinforce the prediction of cardiovascular mortality or events over classical CVRF or imaging‐based detection of atherosclerosis.